Indegene Share Price
657.65+0.00 (+1.90%)
+28.94% past 1 Year
Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.
Price Analysis
About
Stock Analysis (SWOT)
QVT
Peer Stocks
1 week
1 month
1 year
Name
KRT-RRNSE
SAGILITYNSE
PFOCUSNSE
IGILNSE
SYNGENENSE
INDGNNSE
HORIZONINDNSE
NESCONSE
SPARCNSE
SMARTWORKSNSE
Indegene Share Price
657.65+0.00 (+1.90%)
+28.94% past 1 Year
Financial overview
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
CAGR%
Sales
Profits
Returns
ROE
| 10Y | 5Y | 3Y | TTM |
|---|---|---|---|
| 26% | 29% | 15% | 24% |
| 27% | 22% | 15% | -1% |
| - | - | - | 29% |
| 45% | 24% | 21% | 14% |
Peer Comparison
Symbol
KRT-RR
SAGILITY
PFOCUS
IGIL
SYNGENE
INDGN
HORIZONIND
NESCO
SPARC
SMARTWORKS
| Price | M.Cap (₹) | PE Ratio | EPS (₹) | EV/EBITDA | Annual PAT |
|---|---|---|---|---|---|
| 111.88 | ₹50313 Cr | — | — | — | ₹375 Cr |
| 44.4 | ₹20958 Cr | 20.42 | 0.61 | 3.28 | ₹925 Cr |
| 268 | ₹20813 Cr | 129.69 | 0.62 | 11.72 | ₹219 Cr |
| 432.9 | ₹18885 Cr | 28.37 | 4.3 | 16.67 | ₹711 Cr |
| 440 | ₹17665 Cr | 94.92 | 0.8 | 15.74 | ₹317 Cr |
| 656.45 | ₹15552 Cr | 37.83 | 4.67 | 24.19 | ₹401 Cr |
| 48.69 | ₹14097 Cr | — | 0.05 | 0.24 | -₹198 Cr |
| 1,065.55 | ₹7472 Cr | 18.55 | 14.93 | 64.11 | ₹413 Cr |
| 190.93 | ₹6252 Cr | 3.82 | -0.75 | 50.69 | ₹1553 Cr |
| 516.1 | ₹5895 Cr | 104.05 | 2.24 | 89.07 | ₹11 Cr |
Profit & Loss
Consolidated
Standalone
Quarterly
Yearly
₹
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ₹1122 Cr | ₹1063 Cr | ₹1003 Cr | ₹942 Cr | ₹804 Cr | ₹761 Cr | ₹756 Cr | ₹720 Cr | ₹687 Cr | ₹677 Cr | ₹673 Cr | ₹673 Cr | ₹636 Cr | ₹608 Cr | ₹632 Cr |
| ₹15 Cr | ₹29 Cr | ₹11 Cr | ₹19 Cr | ₹20 Cr | ₹22 Cr | ₹26 Cr | ₹38 Cr | ₹21 Cr | ₹23 Cr | ₹23 Cr | ₹13 Cr | ₹12 Cr | ₹29 Cr | ₹13 Cr |
| ₹1137 Cr | ₹1092 Cr | ₹1014 Cr | ₹962 Cr | ₹824 Cr | ₹783 Cr | ₹781 Cr | ₹758 Cr | ₹708 Cr | ₹699 Cr | ₹696 Cr | ₹687 Cr | ₹647 Cr | ₹636 Cr | ₹645 Cr |
| ₹983 Cr | ₹933 Cr | ₹882 Cr | ₹822 Cr | ₹687 Cr | ₹627 Cr | ₹629 Cr | ₹609 Cr | ₹580 Cr | ₹568 Cr | ₹553 Cr | ₹542 Cr | ₹534 Cr | ₹531 Cr | ₹555 Cr |
| ₹201 Cr | ₹203 Cr | ₹174 Cr | ₹179 Cr | ₹160 Cr | ₹177 Cr | ₹173 Cr | ₹170 Cr | ₹148 Cr | ₹151 Cr | ₹162 Cr | ₹162 Cr | ₹133 Cr | ₹125 Cr | ₹111 Cr |
| ₹7 Cr | ₹6 Cr | ₹7 Cr | ₹5 Cr | ₹4 Cr | ₹4 Cr | ₹3 Cr | ₹3 Cr | ₹4 Cr | ₹12 Cr | ₹12 Cr | ₹12 Cr | ₹12 Cr | ₹13 Cr | ₹12 Cr |
| ₹147 Cr | ₹153 Cr | ₹105 Cr | ₹135 Cr | ₹133 Cr | ₹152 Cr | ₹149 Cr | ₹146 Cr | ₹124 Cr | ₹120 Cr | ₹134 Cr | ₹132 Cr | ₹101 Cr | ₹93 Cr | ₹79 Cr |
| ₹112 Cr | ₹116 Cr | ₹80 Cr | ₹103 Cr | ₹102 Cr | ₹116 Cr | ₹118 Cr | ₹110 Cr | ₹92 Cr | ₹88 Cr | ₹95 Cr | ₹99 Cr | ₹75 Cr | ₹68 Cr | ₹49 Cr |
Balance Sheet
Consolidated
Standalone
₹
%
Name
Equity And Liabilities
Share Capital
Share Warrants & Outstandings
Total Reserves
Reserve excluding Revaluation Reserve
Shareholder's Funds
Minority Interest
Secured Loans
Unsecured Loans
Deferred Tax Assets / Liabilities
Other Long Term Liabilities
Long Term Provisions
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Borrowings
Short Term Provisions
Total Current Liabilities
Total Liabilities
Contingent Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Net Block
Capital Work in Progress
Non Current Investments
Long Term Investment
Long Term Loans & Advances
Other Non Current Assets
Total Non-Current Assets
Current Assets Loans & Advances
Currents Investments
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Total Assets
Book Value
Adjusted Book Value
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — | — | — | — |
| ₹48 Cr | ₹48 Cr | ₹44 Cr | ₹44 Cr | ₹35 L | ₹31 L | ₹31 L | ₹79 Cr | ₹79 Cr | ₹79 Cr | ₹79 Cr | ₹79 Cr |
| ₹46 Cr | ₹36 Cr | ₹31 Cr | ₹18 Cr | ₹6 Cr | ₹4 Cr | ₹5 Cr | ₹4 Cr | ₹2 Cr | ₹2 Cr | ₹68 L | ₹79 L |
| ₹3045 Cr | ₹2532 Cr | ₹1353 Cr | ₹1002 Cr | ₹758 Cr | ₹320 Cr | -₹110 Cr | ₹70 Cr | ₹55 Cr | ₹51 Cr | ₹10 Cr | -₹24 Cr |
| ₹3045 Cr | ₹2532 Cr | ₹1353 Cr | ₹1002 Cr | ₹758 Cr | ₹320 Cr | -₹110 Cr | ₹70 Cr | ₹55 Cr | ₹51 Cr | ₹10 Cr | -₹24 Cr |
| ₹3139 Cr | ₹2616 Cr | ₹1429 Cr | ₹1064 Cr | ₹764 Cr | ₹325 Cr | -₹105 Cr | ₹152 Cr | ₹136 Cr | ₹131 Cr | ₹90 Cr | ₹55 Cr |
| ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹9 Cr | ₹89 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹0 | ₹0 | ₹333 Cr | ₹394 Cr | ₹11 Cr | ₹18 Cr | ₹25 Cr | ₹8 Cr | ₹59 L | ₹23 Cr | ₹2 Cr | ₹2 Cr |
| ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹315 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| -₹77 Cr | -₹90 Cr | -₹71 Cr | -₹67 Cr | -₹69 Cr | -₹37 Cr | -₹39 Cr | -₹3 Cr | -₹2 Cr | -₹1 Cr | -₹1 Cr | -₹47 L |
| ₹308 Cr | ₹87 Cr | ₹129 Cr | ₹222 Cr | ₹112 Cr | ₹34 Cr | ₹20 Cr | ₹0 | ₹4 Cr | ₹0 | ₹0 | ₹0 |
| ₹87 Cr | ₹59 Cr | ₹43 Cr | ₹35 Cr | ₹26 Cr | ₹12 Cr | ₹9 Cr | ₹10 Cr | ₹5 Cr | ₹9 Cr | ₹6 Cr | ₹2 Cr |
| ₹319 Cr | ₹56 Cr | ₹435 Cr | ₹584 Cr | ₹80 Cr | ₹27 Cr | ₹331 Cr | ₹16 Cr | ₹8 Cr | ₹30 Cr | ₹7 Cr | ₹4 Cr |
| — | — | — | — | — | — | — | — | — | — | — | — |
| ₹181 Cr | ₹93 Cr | ₹118 Cr | ₹73 Cr | ₹74 Cr | ₹50 Cr | ₹55 Cr | ₹47 Cr | ₹38 Cr | ₹47 Cr | ₹31 Cr | ₹9 Cr |
| ₹777 Cr | ₹395 Cr | ₹403 Cr | ₹354 Cr | ₹305 Cr | ₹128 Cr | ₹82 Cr | ₹55 Cr | ₹81 Cr | ₹52 Cr | ₹45 Cr | ₹75 Cr |
| ₹0 | ₹0 | ₹10 Cr | ₹0 | ₹0 | ₹0 | ₹95 Cr | ₹45 Cr | ₹36 Cr | ₹42 Cr | ₹9 Cr | ₹23 Cr |
| ₹128 Cr | ₹76 Cr | ₹81 Cr | ₹62 Cr | ₹61 Cr | ₹21 Cr | ₹15 Cr | ₹11 Cr | ₹8 Cr | ₹8 Cr | ₹8 Cr | ₹5 Cr |
| ₹1086 Cr | ₹565 Cr | ₹611 Cr | ₹489 Cr | ₹440 Cr | ₹199 Cr | ₹247 Cr | ₹158 Cr | ₹164 Cr | ₹148 Cr | ₹93 Cr | ₹111 Cr |
| ₹4544 Cr | ₹3236 Cr | ₹2475 Cr | ₹2137 Cr | ₹1284 Cr | ₹559 Cr | ₹562 Cr | ₹326 Cr | ₹308 Cr | ₹310 Cr | ₹190 Cr | ₹170 Cr |
| ₹0 | ₹0 | ₹70 L | ₹10 Cr | ₹50 L | ₹50 L | ₹50 L | ₹38 L | ₹38 L | ₹35 L | ₹0 | ₹0 |
| ₹0 | ₹0 | ₹403 Cr | ₹394 Cr | ₹18 Cr | ₹25 Cr | ₹451 Cr | ₹69 Cr | ₹75 Cr | ₹76 Cr | ₹14 Cr | ₹27 Cr |
| — | — | — | — | — | — | — | — | — | — | — | — |
| ₹2354 Cr | ₹1096 Cr | ₹995 Cr | ₹863 Cr | ₹271 Cr | ₹191 Cr | ₹259 Cr | ₹194 Cr | ₹148 Cr | ₹141 Cr | ₹75 Cr | ₹55 Cr |
| ₹543 Cr | ₹418 Cr | ₹349 Cr | ₹199 Cr | ₹134 Cr | ₹105 Cr | ₹140 Cr | ₹90 Cr | ₹74 Cr | ₹60 Cr | ₹41 Cr | ₹26 Cr |
| ₹1812 Cr | ₹678 Cr | ₹646 Cr | ₹664 Cr | ₹138 Cr | ₹86 Cr | ₹119 Cr | ₹104 Cr | ₹75 Cr | ₹81 Cr | ₹33 Cr | ₹29 Cr |
| ₹12 Cr | ₹4 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹34 L | ₹0 |
| ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹13 Cr | ₹0 | ₹0 | ₹81 L | ₹0 | ₹0 |
| ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹13 Cr | ₹0 | ₹0 | ₹81 L | ₹0 | ₹0 |
| ₹41 Cr | ₹22 Cr | ₹35 Cr | ₹20 Cr | ₹16 Cr | ₹14 Cr | ₹11 Cr | ₹37 Cr | ₹35 Cr | ₹36 Cr | ₹16 Cr | ₹7 Cr |
| ₹61 Cr | ₹3 Cr | ₹3 Cr | ₹4 Cr | ₹8 L | ₹6 L | ₹20 L | ₹33 L | ₹64 L | ₹32 L | ₹36 L | ₹0 |
| ₹1925 Cr | ₹706 Cr | ₹684 Cr | ₹688 Cr | ₹154 Cr | ₹100 Cr | ₹144 Cr | ₹142 Cr | ₹134 Cr | ₹127 Cr | ₹53 Cr | ₹40 Cr |
| — | — | — | — | — | — | — | — | — | — | — | — |
| ₹1100 Cr | ₹1290 Cr | ₹797 Cr | ₹614 Cr | ₹120 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹982 Cr | ₹751 Cr | ₹648 Cr | ₹642 Cr | ₹444 Cr | ₹285 Cr | ₹175 Cr | ₹90 Cr | ₹111 Cr | ₹105 Cr | ₹73 Cr | ₹52 Cr |
| ₹382 Cr | ₹375 Cr | ₹191 Cr | ₹86 Cr | ₹517 Cr | ₹140 Cr | ₹180 Cr | ₹37 Cr | ₹9 Cr | ₹18 Cr | ₹10 Cr | ₹16 Cr |
| ₹101 Cr | ₹54 Cr | ₹121 Cr | ₹71 Cr | ₹42 Cr | ₹33 Cr | ₹13 Cr | ₹14 Cr | ₹10 Cr | ₹9 Cr | ₹8 Cr | ₹41 Cr |
| ₹55 Cr | ₹60 Cr | ₹34 Cr | ₹36 Cr | ₹6 Cr | ₹65 L | ₹49 Cr | ₹43 Cr | ₹43 Cr | ₹50 Cr | ₹45 Cr | ₹21 Cr |
| ₹2618 Cr | ₹2530 Cr | ₹1791 Cr | ₹1449 Cr | ₹1130 Cr | ₹459 Cr | ₹418 Cr | ₹185 Cr | ₹174 Cr | ₹182 Cr | ₹137 Cr | ₹130 Cr |
| ₹1532 Cr | ₹1966 Cr | ₹1180 Cr | ₹960 Cr | ₹690 Cr | ₹260 Cr | ₹171 Cr | ₹26 Cr | ₹10 Cr | ₹34 Cr | ₹44 Cr | ₹19 Cr |
| ₹4544 Cr | ₹3236 Cr | ₹2475 Cr | ₹2137 Cr | ₹1284 Cr | ₹559 Cr | ₹562 Cr | ₹326 Cr | ₹308 Cr | ₹310 Cr | ₹190 Cr | ₹170 Cr |
| ₹129 | ₹108 | ₹63 | ₹47 | ₹4,320 | ₹2,045 | -₹700 | ₹448 | ₹352 | ₹329 | ₹70 | -₹156 |
| ₹129 | ₹108 | ₹63 | ₹47 | ₹34 | ₹16 | -₹6 | ₹4 | ₹3 | ₹3 | ₹1 | -₹1 |
Cash Flow
Consolidated
Standalone
₹
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Cash & Cash Equivalent on Amalgamation / Take over / Merger
Effect of Foreign Exchange Fluctuations
Closing Cash & Cash Equivalent
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ₹525 Cr | ₹539 Cr | ₹459 Cr | ₹363 Cr | ₹226 Cr | ₹196 Cr | ₹15 Cr | ₹26 Cr | ₹11 Cr | ₹42 Cr | ₹38 Cr | ₹24 Cr |
| ₹127 Cr | ₹39 Cr | ₹78 Cr | ₹91 Cr | ₹87 Cr | ₹17 Cr | ₹94 Cr | ₹21 Cr | ₹23 Cr | ₹29 Cr | ₹16 Cr | ₹10 Cr |
| ₹146 Cr | ₹24 Cr | ₹96 Cr | -₹216 Cr | ₹54 Cr | ₹9 Cr | -₹59 Cr | ₹35 Cr | -₹3 Cr | -₹26 Cr | -₹18 Cr | -₹15 Cr |
| ₹798 Cr | ₹602 Cr | ₹633 Cr | ₹238 Cr | ₹367 Cr | ₹222 Cr | ₹49 Cr | ₹82 Cr | ₹31 Cr | ₹46 Cr | ₹37 Cr | ₹18 Cr |
| ₹651 Cr | ₹442 Cr | ₹508 Cr | ₹130 Cr | ₹297 Cr | ₹172 Cr | ₹22 Cr | ₹65 Cr | ₹24 Cr | ₹27 Cr | ₹29 Cr | ₹13 Cr |
| -₹512 Cr | -₹683 Cr | -₹327 Cr | -₹893 Cr | -₹160 Cr | -₹24 Cr | -₹19 Cr | -₹19 Cr | -₹21 Cr | -₹77 Cr | -₹17 Cr | -₹6 Cr |
| -₹83 Cr | ₹288 Cr | -₹66 Cr | ₹333 Cr | ₹233 Cr | -₹132 Cr | ₹136 Cr | -₹21 Cr | -₹12 Cr | ₹57 Cr | -₹18 Cr | -₹18 L |
| ₹56 Cr | ₹47 Cr | ₹114 Cr | -₹430 Cr | ₹370 Cr | ₹16 Cr | ₹140 Cr | ₹25 Cr | -₹9 Cr | ₹7 Cr | -₹6 Cr | ₹7 Cr |
| ₹241 Cr | ₹189 Cr | ₹74 Cr | ₹506 Cr | ₹133 Cr | ₹174 Cr | ₹31 Cr | ₹6 Cr | ₹15 Cr | ₹8 Cr | ₹14 Cr | ₹7 Cr |
| ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | -₹54 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹4 Cr | ₹6 Cr | ₹70 L | -₹3 Cr | ₹3 Cr | -₹2 Cr | ₹3 Cr | ₹29 L | ₹23 L | -₹22 L | ₹35 L | ₹26 L |
| ₹301 Cr | ₹241 Cr | ₹189 Cr | ₹74 Cr | ₹506 Cr | ₹133 Cr | ₹174 Cr | ₹31 Cr | ₹6 Cr | ₹15 Cr | ₹8 Cr | ₹14 Cr |
Fundamental Ratios
Consolidated
Standalone

No results found
Indegene Share Price
657.65+0.00 (+1.90%)
+28.94% past 1 Year
Technical meters
Oscillators
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 6
Bearish signals: 0 out of 9 oscillators
RSI
62.80Buy
STOCH %K
74.87Neutral
MACD Level(12,26)
16.62Buy
Ultimate Oscillator
52.48Buy
Aroon Oscillator
80.00Buy
BOP
0.70Buy
CCI
83.52Neutral
Williams %R
-25.13Neutral
Momentum
38.25Buy
Moving averages
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 9
Bearish signals: 0 out of 9 moving averages
EMA 9
646.18Buy
SMA 9
648.00Buy
EMA 21
629.62Buy
SMA 21
622.83Buy
EMA 50
607.52Buy
SMA 50
604.57Buy
EMA 200
560.28Buy
SMA 200
533.16Buy
WMA 20
637.35Buy
Pivot
Pivot
Classic
Resistance 5
725.47
Resistance 4
706.47
Resistance 3
687.47
Resistance 2
668.47
Resistance 1
656.93
Pivot
649.47
Support 1
637.93
Support 2
630.47
Support 3
611.47
Support 4
592.47
Support 5
573.47
High & lows
1 Day
1 Week
1 Month
3 Months
6 Months
Year to Date
1 Year
3 Years
5 Years
10 Years
All Time
Indegene Share Price
657.65+0.00 (+1.90%)
+28.94% past 1 Year
Shareholding summary
Shareholding Pattern
Quarterly
Yearly
Name
Promoters
FII
DII - Others
DII - MFs
Retail & Others
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 |
|---|---|---|---|---|---|
| 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| 12.40% | 9.92% | 10.27% | 11.48% | 11.30% | 10.04% |
| 3.57% | 3.46% | 3.59% | 3.66% | 3.88% | 3.83% |
| 12.25% | 5.28% | 4.70% | 4.40% | 3.07% | 3.37% |
| 71.78% | 81.34% | 81.44% | 80.46% | 81.75% | 82.76% |
Bulk & block deals
Name
Rajesh Bhaskaran Nair
Aarabhi Partners Consultants Llp
Aarabhi Partners Consultants Llp
Rajesh Bhaskaran Nair
Pioneer Investment Fund Scheme Ii
Pi Opportunities Aif V Llp
Pi Opportunities Aif V Llp
Pioneer Investment Fund Scheme Ii
Buoyant Opportunities Strategy - Ii
Bajaj Life Insurance Limited
| Deal Date | Action | Deal Value | Deal Price | Qty Traded | Deal Type | %Stake Traded | Exchange |
|---|---|---|---|---|---|---|---|
| 20 Nov 2026 | Purchase | 25.02 Cr | ₹657 | 3.81 L | Block | 0.158034 | NSE |
| 20 Nov 2026 | Sell | 25.02 Cr | ₹657 | 3.81 L | Block | 0.158034 | NSE |
| 17 Nov 2026 | Sell | 25.02 Cr | ₹655 | 3.82 L | Block | 0.158552 | NSE |
| 17 Nov 2026 | Purchase | 25.02 Cr | ₹655 | 3.82 L | Block | 0.158552 | NSE |
| 08 Oct 2026 | Sell | 119.09 Cr | ₹590 | 20.18 L | Bulk | 0.837821 | NSE |
| 08 Oct 2026 | Purchase | 119.09 Cr | ₹590 | 20.18 L | Bulk | 0.837821 | NSE |
| 08 Oct 2026 | Purchase | 119.09 Cr | ₹590 | 20.18 L | Block | 0.837821 | NSE |
| 08 Oct 2026 | Sell | 119.09 Cr | ₹590 | 20.18 L | Block | 0.837821 | NSE |
| 06 Aug 2026 | Purchase | 25.20 Cr | ₹525 | 4.80 L | Block | 0.199241 | NSE |
| 06 Aug 2026 | Purchase | 50 Cr | ₹525 | 9.52 L | Block | 0.39532 | NSE |
Insider trading & SAST
Client name
Bpc Genesis Fund I Spv Ltd & Pac
Bpc Genesis Fund I- A Spv Ltd
Shouvanik Chatterjee
Anita Nair
Sameer Narendrakumar Lal
Sameer Narendra Lal
Bina Sanjeev Patil (Revised)
Amit Gupta
Bina Sanjeev Patil (Revised)
Bina Sanjeev Patil (Revised)
| Reported on | Client category | Action | %Stake traded | Holding % post deal | Deal value | Deal price | Qty traded | Deal period | Deal mode | Post transaction holding | Insider/SAST | Regulation type | Security type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 28 Aug 2026 | Other | Disposal | 5.75 | — | 0 | — | 1.39 Cr | 06 Aug 2026 | Market | — | SAST | 29(2) | — |
| 28 Aug 2026 | Other | Disposal | 2.98 | — | 0 | — | 71.90 L | 06 Aug 2026 | Market | — | SAST | 29(2) | — |
| 12 Jun 2026 | Designated Person | Disposal | 0.014114 | 0.09 | 1.79 Cr | ₹526.63 | 34 K | 10 Jun 2026 | Market Sale | 2,20,132 | Insider Trading | — | Equity Shares |
| 24 Mar 2026 | Directors Immediate Relative | Acquisition | 0.009237 | 0.1 | 99.98 L | ₹449.76 | 22.23 K | 19 Mar 2026 | Market Purchase | 2,47,074 | Insider Trading | — | Equity Shares |
| 04 Mar 2026 | Designated Person | Disposal | 0.024941 | 0.22 | 2.92 Cr | ₹486.73 | 60 K | 25 Feb 2026 | Market Sale | 5,23,505 | Insider Trading | — | Equity Shares |
| 18 Nov 2025 | Designated Person | Disposal | 0.004165 | 0.24 | 51.26 L | ₹512.57 | 10 K | 14 Nov 2025 | Market Sale | 5,67,515 | Insider Trading | — | Equity Shares |
| 14 Nov 2025 | Designated Person | Disposal | 0.00247 | 0.11 | 31.05 L | ₹523.69 | 5.93 K | 10 Nov 2025 | Market Sale | 2,72,500 | Insider Trading | — | Equity Shares |
| 14 Nov 2025 | Designated Person | Disposal | 0.000916 | 0 | 11.37 L | ₹516.86 | 2.20 K | 11 Nov 2025 | Market Sale | 1,086 | Insider Trading | — | Equity Shares |
| 14 Nov 2025 | Designated Person | Disposal | 0.000208 | 0.12 | 2.63 L | ₹525.70 | 500 | 10 Nov 2025 | Market Sale | 2,78,430 | Insider Trading | — | Equity Shares |
| 14 Nov 2025 | Designated Person | Disposal | 0.000833 | 0.11 | 10.32 L | ₹515.85 | 2 K | 11 Nov 2025 | Market Sale | 2,70,500 | Insider Trading | — | Equity Shares |
Indegene Share Price
657.65+0.00 (+1.90%)
+28.94% past 1 Year
Indegene offers solutions straddling the different stages of the commercialization lifecycle of drugs and medical devices. It caters to the commercial function needs of life sciences companies through its Enterprise
Corporate Actions
Date
Type
Details
Company details
Indegene Share Price
657.65+0.00 (+1.90%)
+28.94% past 1 Year
Corporate filings & documents
Announcements
Annual reports
Concalls & investor presentations
Indegene Share Price
657.65+0.00 (+1.90%)
+28.94% past 1 Year
News
1 of 20
Stock NewsINDGN19 Nov 2026
NULL
Indegene Becomes First Industry Partner In Indo UK Life Sciences Corridor
Stock NewsINDGN19 Nov 2026
Indegene Limited has become the first industry partner for the Indo UK Life Science Corridor established by C CAMP and Imperial College London. The initiative is intended to strengthen entrepreneurship, research collaboration, talent exchange and knowledge sharing across India and the United Kingdom in the life sciences sector.
The five year collaboration is expected to support cooperation among researchers, innovators and startups, including development, validation and deployment of life sciences solutions. It may also facilitate joint fundraising, partnership opportunities and two way assessment of deployment readiness between Indian and UK based teams. The announcement is strategically positive for Indegene because it can improve access to innovation networks, potential clients and emerging life sciences opportunities, although no immediate revenue, investment quantum or earnings guidance was disclosed. The development is therefore likely to have a limited direct near term effect on financial performance.
Indegene Shares See Rs 72.13 Crores BSE Block Trade
Block DealINDGN12 Nov 2026
Indegene Limited reported a BSE block trade involving approximately 1,161,122 shares at Rs 621.25 per share, implying a transaction value of about Rs 72.13 crores. The buyer and seller identities were not disclosed in the available details, and no information was provided on any promoter, institutional, fund, or strategic investor participation. The transaction represents a block transfer of shares, but the associated stake change cannot be determined without the ownership percentage or shareholding data. No premium or discount can be established because a comparable market price at the time of execution was not provided. Follow-through movement in INDGN shares after the transaction was also not specified.
Indegene Reports Strong Q2 Revenue And EBITDA Growth Despite Margin Moderation
ResultINDGN29 Oct 2026
Indegene reported Q2 FY27 revenue from operations of Rs 1,122.3 crores, up 39.6% year on year from Rs 804.2 crores. EBITDA increased 31.9% year on year to Rs 185.7 crores from Rs 140.8 crores, while EBITDA margin declined to 16.6% from 17.5% due to the impact of annual wage increases. Profit after tax rose 10% year on year to Rs 112.3 crores from Rs 102.1 crores. Sequential revenue, EBITDA and PAT changes were not provided in the available information. The combination of robust revenue and profit growth with lower operating margins indicates strong business momentum alongside cost pressure during the quarter.
Indegene Reports Strong Q2 Revenue Growth, Profit Rises Nearly Ten Percent
ResultINDGN29 Oct 2026
Indegene reported consolidated Q2 FY27 revenue of Rs 1,122 crores, up 39.6 percent year on year from Rs 804 crores. EBITDA increased 32.1 percent year on year to Rs 185 crores from Rs 140 crores, while the EBITDA margin declined to 16.5 percent from 17.4 percent. Consolidated net profit rose 9.8 percent year on year to Rs 112 crores from Rs 102 crores. Quarter on quarter comparisons and street expectations were not provided. The result indicates strong revenue expansion, although operating margins moderated.
Indegene Reports Strong Second Quarter Revenue Growth Despite Moderate Profit Expansion
ResultINDGN29 Oct 2026
Indegene reported Q2 FY27 revenue from operations of Rs 1,122.3 crores, up 39.6% year on year from Rs 804.2 crores. Revenue increased 5.6% sequentially from Rs 1,063.1 crores in Q1 FY27. PAT rose 9.8% year on year to Rs 112.3 crores from Rs 102.1 crores. EBITDA was not provided in the available information. The slower growth in PAT relative to revenue indicates margin moderation during the quarter, with wage hikes cited as a factor. No street consensus or formal guidance was provided in the available information. Indegene stated that quarterly revenue growth had exceeded 5% sequentially for the fifth consecutive quarter. The stock closed 0.71% lower at Rs 594.70 before the results announcement.
Indegene Establishes Wholly Owned Step Down Subsidiary In Portugal
Stock NewsINDGN26 Oct 2026
Indegene Limited has incorporated Indegene Portugal, Unipessoal LDA, a step down wholly owned subsidiary in Portugal. The entity was incorporated on 23rd October 2026 and is held 100% by Indegene Ireland Limited, which is wholly owned by Indegene Limited.
Indegene Portugal is currently pre operational and has nil turnover. It is intended to establish the groups presence in Portugal and provide services to life sciences, healthcare and biopharmaceutical customers, including content development, technology support, clinical development support and medical education services. No related party transactions have been reported, and no governmental or regulatory approvals were required for incorporation.
The development is a routine corporate expansion with no disclosed immediate financial contribution, investment quantum or earnings impact. The announcement is expected to have a low near term impact on Indegene shares.
Indegene To Review Second Quarter Financial Results On October 29
Stock NewsINDGN30 Sept 2026
Indegene Limited plans to review its financial results for the second quarter on October 29. The announcement relates to the company’s scheduled results review and does not disclose revenue, profit, EBITDA, dividend, buyback, capital expenditure, management changes, or other corporate actions. No exact financial figures or stock price reaction were provided. The development is routine and may provide investors with an update on operating performance, demand trends, margins, and earnings outlook after the results are reviewed.
Indegene gets preliminary US court nod for class action settlement
Stock NewsINDGN31 Aug 2026
Indegene Limited, listed on NSE as INDGN and BSE as 544172, has received preliminary approval from a US court for a proposed class action settlement involving the company. This development indicates that the court has found the proposed settlement terms to be sufficiently fair and reasonable at a preliminary stage, allowing the formal process of notifying class members and inviting any objections to proceed. While specific financial terms, affected period, and exact allegations underlying the class action are not disclosed in the available context, preliminary approval is a key procedural milestone in US litigation, often preceding a final approval hearing once class members have had an opportunity to respond.
The class action appears to be related to Indegene’s operations or disclosures in the US market, which is a significant geography for the company given its role as a strategic operating partner to global life sciences clients. A settlement, once finally approved, would typically provide legal closure on the claims covered by the class action, reduce ongoing litigation uncertainty, and help the company focus on its core business operations without the overhang of protracted legal proceedings. However, until final approval is granted, the settlement remains subject to further judicial scrutiny and potential objections from class members.
From an earnings and balance sheet perspective, the ultimate impact will depend on the quantum of settlement obligations, any prior provisions already recognized in the financial statements, and whether insurers are sharing part of the payout. In absence of disclosed figures on settlement size or incremental provisions, it is not possible to precisely quantify the effect on profitability or cash flows. Nevertheless, the move toward settlement generally reduces tail legal risk and improves visibility on future liabilities. The news is event-specific to Indegene and does not represent a broader macro or sector-level regulatory action for Indian banking or the wider equity market.
Indegene Ltd sees Rs 39.34 crores NSE block trade at Rs 565
Block DealINDGN20 Aug 2026
Indegene Ltd witnessed a notable block trade on the NSE, with shares worth approximately Rs 39.34 crores changing hands. The transaction involved around 696,205 shares of the company, executed at a price of Rs 565 per share. This points to meaningful institutional or large-investor activity in the counter, even though the specific identities of the buyer and seller have not been disclosed in the available context. The deal size suggests a reasonably large secondary market transaction, but without explicit details on whether it was executed by promoters, strategic investors, domestic institutions, foreign portfolio investors, or mutual funds, the nature of the stake rebalancing remains unspecified.
Given the block size relative to typical daily volumes in mid-cap and emerging healthcare or life-sciences related names on the Indian exchanges, such a transaction is generally interpreted by market participants as signalling either portfolio-level reallocation or negotiated interest from larger investors. However, in the absence of information on the prevailing market price at the time of the trade, no precise comment can be made on whether the Rs 565 execution price represented a premium or discount to the market, nor on any immediate follow-through in the stock price post-deal. There is also no verified data in the context regarding percentage stake change for either side of the transaction. Overall, this remains a routine but sizeable block deal, primarily relevant for investors tracking ownership patterns and liquidity events in Indegene Ltd.
Indegene schedules investor and analyst meetings on August 24-25, 2026
Stock NewsINDGN19 Aug 2026
Indegene has announced that it will hold a series of meetings with various analysts and investors on August 24 and 25. These interactions are typically part of the company’s ongoing investor relations efforts, aimed at providing participants with a detailed understanding of its business operations, strategic priorities, and industry outlook. Such meetings often include updates on recent performance trends, key growth initiatives, and medium-term strategic plans, though no specific agenda or presentation details have been disclosed in the available information.
The announcement does not indicate any corporate action such as mergers and acquisitions, stake sale, buyback, dividend declaration, rights issue, major capex program, management change, or regulatory order. There is also no reference to any changes in guidance, balance sheet structure, leverage levels, or market share metrics, nor is there any quantified financial information such as revenue, EBITDA, net profit, or cash flows linked specifically to these meetings. In the absence of such concrete data, the development is best interpreted as a routine investor engagement initiative rather than a price-sensitive corporate event.
From a market perspective, regular analyst and investor interactions can help improve transparency, strengthen communication with the financial community, and potentially support better-informed valuations over time. However, without any explicit reference to new strategic announcements, earnings surprises, regulatory outcomes, or material business developments, the immediate impact on earnings expectations, risk profile, or near-term stock price performance is likely to be limited. No information has been provided on any contemporaneous stock price movement for Indegene on the day of this announcement. Overall, this appears to be a standard disclosure of scheduled investor meetings, important for engagement but not indicative of a major fundamental shift.
Indegene subsidiary settles lawsuit with potential payout of USD 47.20 lakhs
Stock NewsINDGN19 Aug 2026
Indegene has provided an update on ongoing litigation involving one of its subsidiaries, indicating that the dispute is being resolved through a settlement arrangement. As per the company communication, the settlement amount could reach up to USD 47.20 lakhs. The settlement is being structured explicitly without any admission of guilt by the involved subsidiary or by Indegene, suggesting that the company is opting for a pragmatic resolution to avoid prolonged legal uncertainty and associated costs rather than conceding to the allegations on merit.
While the precise nature of the lawsuit, the underlying claims, and the counterparties have not been detailed in the available update, the quantified potential payout provides some visibility on the financial exposure arising from this matter. Depending on the company’s existing profitability and balance sheet strength, this settlement outflow, if it reaches the upper stated limit, could represent a one-off charge, with limited structural impact on the ongoing operations of the core business. The absence of any admission of guilt may also help contain reputational risk, which is particularly relevant for a knowledge-intensive, client-facing enterprise such as Indegene. There is no specific information yet on how the market has reacted to this disclosure in terms of intraday stock price movement or volume changes. However, investors and market participants are likely to watch subsequent company filings or management commentary for clarity on the timing of the payment, accounting treatment, and whether any provisions have already been recognized in prior financial periods.
Indegene sees Rs 1105.26 crore NSE block trade at Rs 525 per share
Block DealINDGN6 Aug 2026
Indegene reported a large block trade on the NSE, with shares worth Rs 1105.26 crores changing hands in the pre-open session. The transaction involved approximately 2,10,52,478 shares of Indegene, executed at a price of Rs 525 per share. The size of the deal indicates meaningful institutional or strategic interest, although the identities of the buyer and seller have not been disclosed in the available context. In the absence of specific counterparty information, it is unclear whether the trade reflects promoter stake reallocation, entry or exit by a major fund, or a secondary market transaction between large financial investors.
Based on the reported quantum of shares traded, the block likely represents a non-trivial percentage of Indegene’s equity base, which can draw attention from market participants tracking ownership changes and liquidity events. However, since no data is provided on the company’s total outstanding share capital, the exact percentage stake transacted cannot be reliably quantified. The execution at Rs 525 per share in the pre-open window suggests a negotiated price, but without a verified reference to the prevailing market price immediately before the deal, it is not possible to determine whether this block trade occurred at a premium or discount to the last traded price. There is also no validated information on subsequent price movement or intraday volatility following the block trade, so any inference on short-term trading impact would be speculative and is therefore omitted. Overall, the event constitutes a significant, but primarily flow-driven, development for Indegene, with potential implications for liquidity, ownership structure, and investor perception, subject to further disclosures from the exchange or the company.
Indegene Q1 EBITDA grows year-on-year but margin compresses sharply
ResultINDGN30 Jul 2026
Indegene has reported a year-on-year improvement in operating profitability in its latest quarterly numbers, with Q1 EBITDA coming in at Rs 174 crores compared to Rs 155 crores in the corresponding quarter last year. This indicates a healthy increase in absolute EBITDA on an annual basis, reflecting higher operating earnings generation. However, despite the growth in EBITDA, the company has seen a notable compression in profitability ratios at the operating level.
The Q1 EBITDA margin for Indegene has declined to 16.39% versus 20.41% in the same period a year ago. This sharp drop in margin suggests that cost pressures, changes in revenue mix, or higher operating expenses have outpaced the growth in operating profit, leading to weaker efficiency in translating revenues into operating earnings. The combination of higher absolute EBITDA but lower margins points to a situation where the company is scaling up operations but at a relatively higher cost base compared to the previous year.
Key headline takeaway from the result is that operating performance in absolute terms has improved, yet profitability quality has deteriorated on a percentage basis. There is no information in the available context on revenue, PAT, or net margin trends, nor on management commentary, guidance, or market reaction, so the assessment remains focused strictly on the disclosed EBITDA and margin data. Street expectations, if any, are not provided, and therefore cannot be compared. Overall, the result profile reflects a mixed operating picture, combining year-on-year EBITDA growth with significant margin compression.
Indegene Q1 revenue rises sharply year-on-year in reported results
ResultINDGN30 Jul 2026
Indegene has reported a strong year-on-year improvement in its quarterly performance, led primarily by a robust increase in revenue. For the latest reported quarter, the company posted revenue of Rs 1063.00 crores, compared with Rs 761.00 crores in the corresponding quarter of the previous financial year. This represents a substantial year-on-year growth in revenue in rupee terms, signalling healthy expansion in the company’s operating scale and business volumes. The sharp rise in top-line indicates that Indegene is gaining traction in its core operations, potentially reflecting improved client demand, stronger execution, or contribution from new engagements and services. However, detailed profitability metrics such as EBITDA, PAT, and margin trends have not been disclosed in the provided context, and therefore cannot be reliably commented upon. Similarly, there is no verifiable information in the given context on quarter-on-quarter trends, consensus expectations, management commentary, guidance, or stock price reaction, and these aspects are accordingly excluded to preserve data integrity. The focus of the update is thus strictly on the confirmed revenue trajectory, which shows a meaningful upswing in rupee terms and underscores a positive operational trend for the period under review.
Indegene Q1 net profit flat at Rs 116 crores on year-on-year basis
ResultINDGN30 Jul 2026
Indegene has reported consolidated Q1 profit after tax of Rs 116 crores, remaining unchanged compared with Rs 116 crores in the same quarter last year. The available context only specifies the net profit figure and its year-on-year comparison, with no accompanying revenue, EBITDA, or margin disclosure. In the absence of reported revenue and operating metrics, it is not possible to infer top-line performance, cost trends, or operating efficiency changes for the quarter. Similarly, there is no information on quarter-on-quarter movement, so sequential growth or contraction in profitability cannot be assessed from the given data.
No guidance, management commentary, or segmental performance details are provided in the context, which limits visibility into underlying business drivers such as client additions, deal pipeline, or geographic mix. The lack of street consensus or expectations also means that the result cannot be benchmarked against analyst forecasts and therefore cannot be classified as a beat or miss relative to market expectations. There is no data on net or operating margin for the quarter, and no indication of one-offs, exceptional items, or changes in tax rates that may have influenced the reported net profit.
Market reaction, including intraday stock price movement, volumes, and any change in valuations, is not available in the provided context, so the immediate trading impact on INDGN on NSE/BSE cannot be commented upon. Based solely on the flat year-on-year net profit, the earnings outcome appears broadly in-line with the prior-year period, but detailed interpretation of business momentum, sector positioning, or future growth trajectory would require additional verifiable disclosures from company filings or reputable Indian financial media.
Indegene schedules Q1 FY26 earnings conference call on July 31 at 9 am
Stock NewsINDGN10 Jul 2026
Indegene has announced the schedule for its upcoming Q1 FY26 earnings conference call, indicating that the management will brief investors and analysts on the company’s financial and operational performance for the first quarter of the current financial year. The call is slated for July 31 at 9 am, and is part of the company’s regular post-results engagement with the market under SEBI’s disclosure framework. The communication of the call timing suggests that Indegene has either released, or is in the process of releasing, its Q1 FY26 financial results, which will be discussed in detail during this interaction.
Earnings calls for Indegene typically cover revenue growth trends across key geographies, margin performance, profitability metrics, and updates on strategic initiatives within its life sciences and healthcare solutions business. Management generally provides insights into demand conditions in major markets such as the US and Europe, commentary on client spending behavior, and a roadmap for future growth. The scheduled call is therefore an important event for institutional and retail investors tracking Indegene’s earnings trajectory, business momentum, and any qualitative guidance on the coming quarters.
From a market perspective, the announcement of the Q1 FY26 earnings call is a routine corporate disclosure and forms part of Indegene’s standard investor relations calendar. While the precise financial figures, segment performance and management commentary will only be known once the call and the accompanying disclosures are completed, the scheduling itself reinforces the company’s focus on transparency and regular communication with stakeholders. Traders and long-term investors may monitor subsequent detailed results, presentation materials and transcripts to reassess their earnings expectations, but the current development on its own is unlikely to drive significant immediate changes in market valuations without incremental information on growth, margins or guidance.
Indegene informs about analyst meet
Stock NewsINDGN4 Jun 2026
NULL
Indegene: Recognized As A Top Performer In Isg Provider Lens™ For Life Sciences Digital Services 2026.
Stock NewsINDGN4 May 2026
Indegene: Recognized As A Top Performer In Isg Provider Lens™ For Life Sciences Digital Services 2026.
Indegene gains even after reporting 32% fall in Q4 consolidated net profit
Stock NewsINDGN30 Apr 2026
The total consolidated income of the company increased by 29.83% at Rs 1014.20 crore for Q4FY26

